GHK-Cu dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 50 mg vial reconstituted with 2 mL bacteriostatic water gives 25 mg/mL. A 2 mg subcutaneous dose equals 8 units on a U100 insulin syringe. Topical formulations are usually pre-formulated at 0.05% to 3%.

   Open tool →
2. 2

   Measure the dose

   Typical GHK-Cu dose is 2 mg (Topical: 0.05% to 3% formulations applied 1 to 2x daily. Subcutaneous (anecdotal): 1 to 3 mg daily.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer daily. Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Topical use is continuous. Anecdotal SC protocols run 4 to 8 weeks on, then off, with no controlled human cycling data.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: mild erythema at topical site; transient itch; blue-green discoloration of injection site (copper); rare contact dermatitis. Stop or reduce dose if tolerability breaks down.

Why this dose

Tripeptide that chelates Cu(II) and delivers it to copper-dependent enzymes (lysyl oxidase, superoxide dismutase). Modulates expression of >4000 genes toward a younger profile in fibroblast culture, including upregulation of decorin and downregulation of pro-inflammatory cytokines.

The typical dose (2 mg) reflects Topical: 0.05% to 3% formulations applied 1 to 2x daily. Subcutaneous (anecdotal): 1 to 3 mg daily.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

GHK-Cu is administered via the topical or subcutaneous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 24 hours after administration. Peak effect lands near 1 weeks post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life of injected GHK-Cu is short (~30 minutes). Topical reservoir effects within skin layers persist longer.

Cycling and tolerance

Topical use is continuous. Anecdotal SC protocols run 4 to 8 weeks on, then off, with no controlled human cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Endogenous tripeptide that binds copper(II); plasma levels decline ~60% from age 20 to 60
• Topical RCTs show improvement in skin firmness, fine lines, and barrier function over 12 weeks
• Wound-healing models report accelerated re-epithelialization in diabetic and aged skin
• Pickart gene-expression analyses show reset of >4000 genes toward a younger expression profile in cell culture
• Anecdotal subcutaneous longevity protocols use 1 to 3 mg daily; no human longevity RCTs exist
• Hair-growth claims rest on small open-label trials and topical scalp formulations

Side effects and interactions

Common side effects

• mild erythema at topical site
• transient itch
• blue-green discoloration of injection site (copper)
• rare contact dermatitis

Notable interactions

• topical retinoids (minor): additive irritation; alternate days or apply at different times
• topical vitamin C (ascorbic acid) (minor): ascorbate reduces Cu(II) to Cu(I), which can destabilize the GHK-Cu complex; separate by 30 minutes

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full GHK-Cu profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Topical OTC (cosmetic); injectable not FDA approved; research-chemical status

Pregnancy

Insufficient data; topical use likely low-risk; injectable not recommended

Legal status

Topical cosmetics legal in most jurisdictions; injectable form not FDA approved for any indication; research-use-only grey market

Do not use if

• copper allergy
• Wilson disease
• open wound near injection site (caution)
• pregnancy (no data)

Related research